Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Clin Cancer Res. 2012 Aug 7;18(19):5290–5303. doi: 10.1158/1078-0432.CCR-12-0563

Figure 5.

Figure 5

A GEM model of luminal breast cancer is exceptionally sensitive to combined PI3K/mTOR/ MEK inhibition. MMTV-c-neu mice were stratified by tumor size and randomly assigned to a treatment cohort. A, lapatinib and combined AZD/BEZ treatment regimens provide nearly complete tumor regression as measured by percent change in tumor volume at day 21. B, waterfall plot distribution of tumor response from combined AZD/BEZ compared with the average tumor size of untreated animals on day 21. AZD/BEZ response represents the best response seen on day 21 or beyond. Negative values indicate tumor shrinkage. C, combined AZD/ BEZ treatment prolonged median survival from 29 to 173 days, whereas lapatinib prolonged median survival to only 112 days; MS, median survival.